CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 88 enrolled
Drug / intervention
Naloxone +3 moredrug
Likely dose
Naloxone 0.15 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04034004
NCT04034004Early Ph 1Completed

The Role of Endogenous Opioids in Mindfulness-based Chronic Pain Relief

University of California, San Diego·interventional·Posted Jul 26, 2019·Updated Oct 11, 2023

In Brief

A Early Phase 1 clinical trial evaluating Mindfulness, Naloxone, and 2 other interventions for Pain. Completed, enrolled 88 participants across 2 sites.

Detailed Summary

The purpose of this research study is to see if and how mindfulness meditation affects pain. Specifically, we are interested in assessing if mindfulness is associated with the release of naturally occurring opiates in the body, in response to intravenous (IV) administration of the opioid antagonist naloxone during a chronic low back pain provoking procedure.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain
CountriesUnited States

Timeline

Early Ph 1CompletedFinished
2020202120222023202420252026
First PostedJul 26, 2019
Enrollment StartJan 1, 2021
Primary CompletionDec 22, 2022
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 6.9 years ago

Interventions

Mindfulnessbehavioral

A well-validated brief meditation-based mental training regimen \[four sessions; 20 min/session\] is used to teach patients to independently practice closing their eyes and take a deep breath every few minutes.

Naloxonedrug

A 0.15 mg/kg bolus dose of naloxone (Naloxone hydrochloride, Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California) in 25ml normal saline will be administered over 10 minutes. The investigators also will administer a supplementary IV infusion dose of 0.1mg/kg/hour naloxone immediately after bolus infusion will cease till the end of the experiment.

Salineother

A 0.15 mg/kg bolus dose of saline in 25ml normal saline will be administered over 10 minutes. The investigators also will administer a supplementary IV infusion dose of 0.1mg/kg/hour saline immediately after bolus infusion will cease till the end of the experiment.

Meditationbehavioral

A well-validated brief meditation-based mental training regimen \[four sessions; 20 min/session\] is used to teach patients to independently practice closing their eyes and take a deep breath every few minutes.